Safety and tolerability of ACZ885 (Canakinumab) in patients with gout

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-003414-17

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The purpose of this third extension study is to provide additional long-term safety and tolerability data of canakinumab over an 18-month time period on patients who have completed the extension studies CACZ885H2356E2 or CACZ885H2357E2.


Critère d'inclusion

  • Treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffective